SSI Strategy, a Parsippany, NJ-based Life Sciences consultancy, received a growth investment from Amulet Capital Partners.
The amount of the deal was not disclosed.
The company intends to use the funds to accelerate growth and expand strategic services to support Medical, Clinical and other critical path functions at the C-level of Life Sciences companies.
Led by Doug Locke, CEO, SSI Strategy combines medical, clinical and pharmacovigilance domain expertise, and operating experience to provide support to clients. Its staff of ex-Chief Medical Officers and former Heads of Medical Affairs, Clinical Development and Safety work to ensure the right balance of medical and business focus to drive outcomes for clients.